This study aimed to explore the effect of myricitrin on osteoblast differentiation in mice immortalised bone marrow mesenchymal stem cells (imBMSCs). Additionally, ovariectomy (OVX) mice were employed to examine the effect of myricitrin on bone trabecular loss in vivo. The effect of myricitrin on the proliferation of imBMSCs was evaluated using a cell counting kit‐8 assay. Alizarin red staining, alkaline phosphatase staining were performed to elucidate osteogenesis. Furthermore, qRT‐PCR and western blot determined the expression of osteo‐specific genes and proteins. To screen for candidate targets, mRNA transcriptome genes were sequenced using bioinformatics analyses. Western blot and molecular docking analysis were used to examine target signalling markers. Moreover, rescue experiments were used to confirm the effect of myricitrin on the osteogenic differentiation of imBMSCs. OVX mice were also used to estimate the delay capability of myricitrin on bone trabecular loss in vivo using western blot, micro‐CT, tartaric acid phosphatase (Trap) staining, haematoxylin and eosin staining, Masson staining and immunochemistry. In vitro, myricitrin significantly enhanced osteo‐specific genes and protein expression and calcium deposition. Moreover, mRNA transcriptome gene sequencing and molecular docking analysis revealed that this enhancement was accompanied by an upregulation of the PI3K/AKT signalling pathway. Furthermore, copanlisib, a PI3K inhibitor, partially reversed the osteogenesis promotion induced by myricitrin. In vivo, western blot, micro‐CT, hematoxylin and eosin staining, Masson staining, Trap staining and immunochemistry revealed that bone trabecular loss rate was significantly alleviated in the myricitrin low‐ and high‐dose groups, with an increased expression of osteopontin, osteoprotegerin, p‐PI3K and p‐AKT compared to the OVX group. Myricitrin enhances imBMSC osteoblast differentiation and attenuate bone mass loss partly through the upregulation of the PI3K/AKT signalling pathway. Thus, myricitrin has therapeutic potential as an antiosteoporosis drug.
Background: Osteoporosis is characterized by reduced bone mass and destruction of trabecular bone microstructure, increasing fracture risk. Newly marketed drugs have certain advantages in osteoporosis, but high health care expenditures and side effects limit their application. Therefore, it is urgent to explore new approaches to break the therapeutic deadlock in the current clinical condition. Myricitrin has many biological activities. However, the effect on antiosteoporosis has not fully been elucidated yet.Methods: The effect of myricitrin on the proliferation of immortalized bone marrow mesenchymal stem cells was evaluated using Cell Counting Kit-8 assays. Alizarin Red staining, Alkaline phosphatase staining, and activity were performed to elucidate osteogenesis. qRT-PCR and Western blot were performed to evaluate the expression of osteo-specific genes and proteins. To screen for candidate targets, sequencing of mRNA transcriptome genes was used through bioinformatics analysis. Western blot and Molecular docking analysis were used to examine target signaling markers. Rescue experiments were used to confirm myricitrin can enhance osteogenic differentiation of imBMSCs reversely. Moreover, ovariectomy mice were used to assess the effect of myricitrin on bone loss in vivo by Western blot, Micro-CT, Hematoxylin and Eosin staining, and immunochemistry.Results: Myricitrin can significantly enhance osteo-specific genes and proteins expression, alkaline phosphatase activity, and calcium deposition in imBMSCs in vitro. These phenomena were accompanied by an upregulation of the PI3K/AKT signaling pathway via bioinformatics analysis and Western blot. In addition, the improvement of osteogenesis due to myricitrin intervention was partially reversed by copanlisib, which is a PI3K inhibitor. Osteopontin (OPN), osteoprotegerin (OPG), p-PI3K, and p-AKT were significantly increased in the low dose and high dose myricitrin groups compared with the OVX group. Micro-CT, H&E staining, and immunochemistry showed that bone mass was significantly increased in low dose and high dose groups compared with the OVX group. Furthermore, myricitrin can attenuate bone loss in ovariectomy mice.Conclusion: These data suggest that myricitrin enhances the osteogenic differentiation of imBMSCs, partly via activation of the PI3K/AKT signaling pathway. Myricitrin may be a potential drug development for the treatment of postmenopausal osteoporosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.